Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes (T2D) is a highly prevalent disorder that affects millions of people worldwide. The hallmark of T2D is hyperglycemia and, while many treatment modalities exist, achieving and maintaining glycemic control can be challenging. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an appealing treatment option as they improve glycemic control, reduce weight, and limit the risk of hypoglycemia. Lixisenatide is a once-daily GLP-1 RA that has been evaluated in the GetGoal clinical trial program and has demonstrated efficacy and tolerability across a spectrum of patients. The feature that most distinguishes lixisenatide from other GLP-1 RAs is its ability to substantially reduce postprandial glucose (PPG) for the meal immediately following injection. Because of its positive effects on PPG, lixisenatide is being considered as a replacement for prandial insulin, and a fixed dose combination product containing lixisenatide and basal insulin is in development. Lixisenatide is a promising new addition to the antidiabetic armamentarium, but due to the lack of real-world experience with the drug, its exact place in therapy is unknown.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a synthetic analog of its endogenous exendin-4, compared with exendin-4, LIXI deleted one proline and added six lysine residues, which increased its binding affinity with the GLP-1R by four times and increased its circulating half-life (58, 59).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [58]
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Seino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Riddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Research works printed but not linked: 8
- Becker R., 2010, Diabetologia, 53, S339
- Brigham and Women’s Hospital (2015) No increased cardiovascular risk detected for new diabetes medication, press release, 8 June. Available at: http://www.brighamandwomens.org/about_bwh/publicaffairs/news/pressreleases/PressRelease.aspx?PageID=%202082 (accessed 24 August 2015).
- Distiller L., 2008, Diabetes, 57
- Gomez-Huelgas R., 2014, Diabetes, 63, A254
- Liu Y., 2009, Diabetes, 59, A149
- Liu Y., 2010, Diabetes, 59
- Seino Y., 2012, J Diabetes Investig, 3
- Zealand Pharma (2015) Zealand informs of updates given by Sanofi on Lyxumia® and LixiLan on an IR thematic conference call on diabetes, Press release no. 4/2015, 9 June. Available at: https://globenewswire.com/news-release/2015/06/09/743262/0/en/files/346068/0/PR%2004–15_0906%20-%20Updates%20by%20Sanofi%20on%20Lyxumia%20and%20Lixilan%20-%20ENG_Final.pdf (accessed 24 August 2015).
Cited by
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Anti-diabetic drugs recent approaches and advancements
Dowarah, J., & Singh, V. P. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115263 · Cited by 227
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 71
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 73
Metadata
- Authors
- Anderson, S. L., & Trujillo, J. M.
- Affiliations
- University of Colorado Anschutz (US)
- Corresponding author
- Trujillo, Jennifer M.
- Venue
- Therapeutic Advances in Chronic Disease
- Publisher
- SAGE Publications
- Published
- 2015-10-07
- Volume
- 7
- Issue
- 1
- Pages
- 4-17
- ISSN
- 2040-6223 (ISSN-L)
- 2040-6231
- PMC
- PMC4707429
- OpenAlex
- W2409754321
- Cited by
- 36
- References
- 27
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 4
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Chronic Disease (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- lixisenatide, type 2 diabetes, GLP-1 receptor agonists, glycemic control, postprandial blood glucose, drug tolerability, antidiabetic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. https://app.cochat.ai/papers/10.1177/2040622315609312
- The paper
- Anderson, S. L., & Trujillo, J. M. (2016). Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/2040622315609312
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.